赵多多;庄俊玲;
ZHAO Duo-duo;ZHUANG Jun-ling;Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院血液内科

摘要(Abstract)：

多发性骨髓瘤具有独特的骨病表现,由于破骨细胞激活和成骨细胞功能抑制导致溶骨性破坏和严重骨质疏松。骨病严重程度对患者生活质量和生存均有负面影响。普通X线检出骨病的灵敏度很低,CT的灵敏度虽明显提高,但难以检出骨外病变。功能性影像方法(主要包括磁共振弥散加权成像和正电子发射断层显像/计算机体层成像)不仅能发现早期溶骨病灶,且在评估全身肿瘤负荷和缓解后微小残留病变方面更有优势。本文将对这些方面的进展进行综述。
Multiple myeloma has unique manifestations of bone disease, mainly presenting as osteolytic lesions and diffuse osteoporosis as a result of over-activation of osteoclasts and suppression of osteoblasts. The severity of myeloma bone disease is negatively correlated with quality of life and survival. Plain X ray has low sensitivity to contour destructive bone lesions. Whole body low dose CT does not differentiate active foci from tranquil ones. Functional imaging including diffuse weighted imaging-magnetic resonance imaging(DWI-MRI) and positron emission tomography/computed tomography(PET/CT) are more sensitive in evaluation of comprehensive tumor load and detection of early disease. Moreover, minimal residue disease detected by DWI-MRI or PET/CT is a complement of flow cytometry and predicts progressive disease in patients achieving complete response. In this article, we summarized the role of imaging methods in evaluating myeloma bone disease and tumor load.

关键词(KeyWords)： 多发性骨髓瘤;影像;骨病;微小残留病变;肿瘤负荷
multiple myeloma;imaging;bone disease;minimal residual disease;tumor load

Abstract:

Keywords:

基金项目(Foundation): 北京市自然科学基金(7192175)

作者(Authors): 赵多多;庄俊玲;
ZHAO Duo-duo;ZHUANG Jun-ling;Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1] 张之南,单渊东,李蓉生,等.协和血液病学[M].北京:中国协和医科大学出版社,2004:497.
• [2] Roodman GD.Pathogenesis of myeloma bone disease[J].Blood Cells Mol Dis,2004,32:290- 292.
• [3] Dimopoulos M,Terpos E,Comenzo RL,et al.International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma[J].Leukemia,2009,23:1545- 1556.
• [4] Derlin T,Bannas P.Imaging of multiple myeloma:current concepts[J].World J Orthop,2014,5:272- 282.
• [5] Regelink JC,Minnema MC,Terpos E,et al.Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease:a systematic review[J].Br J Haematol,2013,162:50- 61.
• [6] Horger M,Claussen CD,Bross-Bach U,et al.Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma:an alternative to conventional radiography[J].Eur J Radiol,2005,54:289- 297.
• [7] Rajkumar SV,Dimopoulos MA,Palumbo A,et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J].Lancet Oncol,2014,15:538- 548.
• [8] Baur-Melnyk A,Buhmann S,Becker C,et al.Whole-body MRI versus whole-body MDCT for staging of multiple myeloma[J].AJR Am J Roentgenol,2008,190:1097- 1104.
• [9] Dimopoulos MA,Hillengass J,Usmani S,et al.Role of magnetic resonance imaging in the management of patients with multiple myeloma:a consensus statement[J].J Clin Oncol,2015,33:657- 664.
• [10] Walker R,Barlogie B,Haessler J,et al.Magnetic res-onance imaging in multiple myeloma:diagnostic and clinical implications[J].J Clin Oncol,2007,25:1121- 1128.
• [11] Hillengass J,B?uerle T,Bartl R,et al.Diffusion-weighted imaging for non- invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease:a comparative study with histology[J].Br J Haematol,2011,153:721- 728.
• [12] Rasche L,Alapat D,Kumar M,et al.Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma[J].Leukemia,2019,33:1713- 1722.
• [13] Cavo M,Terpos E,Nanni C,et al.Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders:a consensus statement by the International Myeloma Working Group[J].Lancet Oncol,2017,18:206- 217.
• [14] Usmani SZ,Mitchell A,Waheed S,et al.Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3[J].Blood,2013,121:1819- 1823.
• [15] Zamagni E,Patriarca F,Nanni C,et al.Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation[J].Blood,2011,118:5989- 5995.
• [16] Zamagni E,Nanni C,Mancuso K,et al.PET/CT Improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma[J].Clin Cancer Res,2015,21:4384- 4390.
• [17] Puig N,Sarasquete ME,Balanzategui A,et al.Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma.A comparative analysis with flow cytometry[J].Leukemia,2014,28:391.
• [18] Martinez-Lopez J,Lahuerta JJ,Pepin F,et al.Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J].Blood,2014,123:3073- 3079.
• [19] Moreau P,Attal M,Hulin C,et al.Bortezomib,thalidomide,and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA):a randomised,open-label,phase 3 study[J].Lancet,2019,394:29- 38.
• [20] 金媛媛,庄俊玲.新药时代自体造血干细胞移植在多发性骨髓瘤一线治疗中的地位[J].协和医学杂志,2018,9:219- 223.
• [21] Kumar S,Paiva B,Anderson KC,et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J].Lancet Oncol,2016,17:e328-e346.
• [22] Rasche L,Angtuaco E,MC Donald JE,et al.Low expression of Hexokinase- 2 is associated with false-negative FDG-positron emission tomography in multiple myeloma[J].Blood,2017,130:30- 34.
• [23] Lapa C,Garcia-Velloso MJ,Lückerath K,et al.11C-Methionine-PET in multiple myeloma:a combined study from two different institutions[J].Theranostics,2017,7:2956- 2964.
• [24] Philipp-Abbrederis K,Herrmann K,Knop S,et al.In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma[J].EMBO Mol Med,2015,7:477- 487.